Free tool
FAERS Monitor: Neulasta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125031 or its brand name (Neulasta, Pegfilgrastim). Reports on generic versions are filed under their own applications.
Reports
98,636
Serious
28,802
29% of reports
Hospitalization
15,436
Death reported
5,283
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device adhesion issue11,933
- wrong technique in product usage process10,265
- unintentional medical device removal8,999
- device malfunction6,943
- device use error6,057
- device issue5,174
- accidental exposure to product5,007
- febrile neutropenia3,819
- off label use3,795
- device occlusion3,368
- bone pain2,947
- death2,771
- neutropenia2,689
- fatigue2,673
- pyrexia2,518
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 346 |
| 2005 | 350 |
| 2006 | 391 |
| 2007 | 595 |
| 2008 | 910 |
| 2009 | 945 |
| 2010 | 883 |
| 2011 | 1,103 |
| 2012 | 1,563 |
| 2013 | 1,529 |
| 2014 | 2,667 |
| 2015 | 2,065 |
| 2016 | 5,281 |
| 2017 | 8,064 |
| 2018 | 14,149 |
| 2019 | 8,391 |
| 2020 | 11,660 |
| 2021 | 11,387 |
| 2022 | 8,427 |
| 2023 | 7,319 |
| 2024 | 5,726 |
| 2025 | 3,097 |
| 2026 | 1,788 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,955,523 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| unintentional medical device removalSignal | 8,999 | 740.7 | 709.3 | 1,482,382 |
| device adhesion issueSignal | 11,933 | 740.2 | 713.0 | 1,965,775 |
| device occlusionSignal | 3,368 | 66.8 | 64.3 | 166,050 |
| device use errorSignal | 6,057 | 44.8 | 43.6 | 214,509 |
| device malfunctionSignal | 6,943 | 23.3 | 22.7 | 133,772 |
| device issueSignal | 5,174 | 13.0 | 12.6 | 54,196 |
| febrile neutropeniaSignal | 3,819 | 13.0 | 12.6 | 39,858 |
| wrong technique in product usage processSignal | 10,265 | 11.3 | 11.1 | 92,615 |
| bone painSignal | 2,947 | 11.2 | 10.8 | 26,183 |
| accidental exposure to productSignal | 5,007 | 10.8 | 10.5 | 42,743 |
| neutropeniaSignal | 2,689 | 4.3 | 4.1 | 6,671 |
| pyrexia | 2,518 | 1.6 | 1.5 | 504 |
| off label use | 3,795 | 0.9 | 0.9 | 25 |
| fatigue | 2,673 | 0.7 | 0.7 | 273 |
| death | 2,771 | 0.7 | 0.7 | 417 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.